Evaluating the re-identification risk of a clinical study report anonymized under EMA Policy 0070 and Health Canada Regulations

BACKGROUND: Regulatory agencies, such as the European Medicines Agency and Health Canada, are requiring the public sharing of clinical trial reports that are used to make drug approval decisions. Both agencies have provided guidance for the quantitative anonymization of these clinical reports before...

Descripción completa

Detalles Bibliográficos
Autores principales: Branson, Janice, Good, Nathan, Chen, Jung-Wei, Monge, Will, Probst, Christian, El Emam, Khaled
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029478/
https://www.ncbi.nlm.nih.gov/pubmed/32070405
http://dx.doi.org/10.1186/s13063-020-4120-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029478/
https://www.ncbi.nlm.nih.gov/pubmed/32070405
http://dx.doi.org/10.1186/s13063-020-4120-y

Ejemplares similares